Precision BioSciences CSO to Join Gene Therapy Session at DIA 2018

Precision BioSciences CSO Derek Jantz will present and join a panel
discussion during the DIA (Drug Information Association) 2018 conference
session #285, Gene
Therapy: Advances in Translating Technology. Dr. Jantz will share
Precision’s approach to advancing genome editing into the clinic and his
perspectives from over 20 years of designing and developing gene editing
tools for therapeutic applications. The panel will be chaired by Peter
Marks, Director of CBER at FDA, and will also include Terence Flotte,
Dean of the School of Medicine at University of Massachusetts; David
Davidson, CMO at bluebird bio; and Michael Havert, CMC reviewer at the
FDA. This session will address the existing regulatory framework as well
as recent advances in the field of gene therapy.

About Precision BioSciences

Precision BioSciences is dedicated to improving life. Our mission is to
cure genetic disease, overcome cancer, and feed the planet. We are
striving to achieve this goal with ARCUS, our therapeutic-grade,
naturally-derived genome editing system that combines both specificity
and efficacy to help overcome life’s greatest genetic challenges. For
additional information, please visit www.precisionbiosciences.com.

About DIA

(founded as the Drug Information Association) is a global association
that mobilizes life science professionals from across all areas of
expertise to engage with patients, peers and thought leaders in a
neutral environment on the issues of today and the possibilities for
tomorrow. As a member-driven, volunteer organization, professionals from
80 countries have affected healthcare outcomes, by engaging with DIA
through an unparalleled network, educational offerings, and professional
development opportunities.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180620005973/en/